Performance analysis of Compass Therapeutics (CMPX)
Annual Return
Over the past 3 years, CMPX has had an average annual return of -7.35%, underperforming the benchmark SPY, which returned +19.63% annual.
Over the past 5 years, CMPX has had an average annual return of -15.77%, underperforming the benchmark SPY, which returned +12.73% annual.
Since Apr 5, 2021, CMPX has had an average annual return of -23.20%, underperforming the benchmark SPY, which returned +13.74% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -60.89% | +270.34% | -7.03% | -68.99% | +58.70% | -62.71% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +19.17% | -11.71% | -6.36% | -66.55% | +34.49% | -8.00% | -4.08% | -60.89% | |||||
| 2025 | +122.04% | -9.93% | -34.50% | -2.10% | +12.93% | +23.80% | +14.22% | +17.52% | +0.29% | +6.85% | +55.09% | -7.42% | +270.34% |
| 2024 | -16.68% | +36.95% | +11.22% | -27.26% | -2.07% | -29.11% | +3.06% | +53.38% | +16.46% | -10.90% | -0.57% | -11.05% | -7.03% |
| 2023 | -20.48% | -5.25% | -13.73% | -7.95% | -3.64% | +9.64% | -9.76% | -18.81% | -15.43% | -8.63% | -8.36% | -5.46% | -68.99% |
| 2022 | -44.78% | +15.98% | -32.50% | +8% | +106.09% | -13.10% | -1.89% | +5.75% | -17.09% | +38.63% | +30.04% | +22.40% | +58.70% |
| 2021 | -17.65% | -40.00% | +13.09% | +3.17% | -28.57% | -2.57% | -11.44% | +4.95% | +0% | -62.71% |
Drawdown analysis of Compass Therapeutics (CMPX)
The maximum drawdown for the CMPX was -90.91%, occurring on Jul 5, 2024. This drawdown has not yet recovered.
The current CMPX drawdown is -76.13%.
Since Apr 5, 2021 CMPX has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 1 time
- 10% or more: 1 time
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -90.91% | Apr 16, 2021 | 809 | Jul 5, 2024 | Ongoing | Ongoing | Ongoing |